首页> 外文期刊>Nephron >Sulfated Hyaiuronic Acid, a Potential Selectin Inhibi-tor, Ameliorates Experimentally Induced Crescentic Glomerulonephritis
【24h】

Sulfated Hyaiuronic Acid, a Potential Selectin Inhibi-tor, Ameliorates Experimentally Induced Crescentic Glomerulonephritis

机译:硫酸透明质酸,一种潜在的选择素抑制剂,改善了实验性新月形肾小球肾炎。

获取原文
获取原文并翻译 | 示例
           

摘要

Background/Aims: Sulfated polysaccharides are known to interfere with the binding of selectins and their ligands. Recently, we demonstrated that sulfated hyaiuronic acid (SHA), a synthetic sulfated polysaccharide, showed preventive and therapeutic effects on experimental mesangial proliferative glomerulonephritis. Here we evaluated the protective potential of SHA on crescentic glomerulonephritis, using nephrotoxic serum (NTS) nephritis in Wistar-Kyoto (WKY) rats. Methods: Crescentic glomerulonephritis was induced by injection of NTS in WKY rats. Rats subsequently received intraperitoneal administration of SHA (0.5 or 1.5 mg/kg/day) or non-sul-fated hyaiuronic acid (HA) (1.5 mg/kg/day) for 14 days. The urinary protein excretion was measured, and expression of selectins, intraglomerular leukocytes and crescent formation were examined by immunohisto-chemistry. In addition, we examined the urinary protein excretion of SHA (1.5 mg/kg/day) administered from day 7 after the induction of crescentic glomerulonephritis.Results: The expression of P-selectin was increased in the glomerulus of crescentic glomerulonephritis. SHA reduced proteinuria, macrophage infiltration, and crescent formation in a dose-dependent manner. Furthermore, administration of SHA (1.5 mg/kg/day) from day 7 also reduced the urinary protein excretion on day 14 compared with that in saline and HA group. Conclusion: Our results suggest that SHA inhibits intraglomerular infiltration of macrophages, and prevents progression of experimental crescentic glomerulonephritis. Sulfated polysaccharides might be beneficial for the treatment of crescentic glomerulonephritis.
机译:背景/目的:已知硫酸化多糖会干扰选择素及其配体的结合。最近,我们证明了硫酸化透明质酸(SHA),一种合成的硫酸化多糖,对实验性系膜增生性肾小球肾炎显示出预防和治疗作用。在这里,我们使用Wistar-Kyoto(WKY)大鼠的肾毒性血清(NTS)肾炎评估了SHA对新月体性肾小球肾炎的保护潜力。方法:注射NTS诱导WKY大鼠新月型肾小球肾炎。随后,大鼠腹膜内给予SHA(0.5或1.5 mg / kg /天)或非磺化透明质酸(HA)(1.5 mg / kg /天),持续14天。测量尿蛋白排泄,并通过免疫组织化学检查选择蛋白的表达,肾小球内白细胞和新月形成。此外,我们检测了从诱导新月型肾小球肾炎后第7天开始服用SHA(1.5 mg / kg /天)的尿蛋白排泄。结果:P-选择蛋白在新月型肾小球肾小球的表达增加。 SHA以剂量依赖的方式减少蛋白尿,巨噬细胞浸润和新月形形成。此外,与生理盐水和HA组相比,从第7天开始服用SHA(1.5 mg / kg /天)也减少了第14天的尿蛋白排泄。结论:我们的结果表明SHA抑制巨噬细胞的肾小球内浸润,并防止实验性新月形肾小球肾炎的进展。硫酸多糖可能对治疗新月型肾小球肾炎有益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号